Core Viewpoint - Peijia Medical expects revenue in 2025 to be approximately 7.0 to 7.2 billion yuan, representing a year-on-year growth of about 13.7% to 17.0% driven by strong performance across all three product lines in the neurointervention business and an expanding market share in the transcatheter aortic valve replacement (TAVR) sector, primarily due to the successful launch of the high-end TaurusMax 3D adjustable TAVR system [1] Group 1 - The expected revenue for 2025 is projected to be around 7.0 to 7.2 billion yuan [1] - The year-on-year growth rate is estimated to be between 13.7% and 17.0% [1] - The growth is attributed to strong performance in all three product lines of the neurointervention business [1] Group 2 - The market share in the TAVR sector is continuously expanding [1] - The expansion is mainly driven by the successful launch of the TaurusMax 3D adjustable TAVR system [1]
沛嘉医疗：预计2025年收入约700-7.2亿元，同比增长约13.7-17.0%